Publication | Closed Access

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

Pro-drug Sf1126MedicinePharmacologyAdvanced Solid TumoursPharmacotherapyPan-pi3k/mtorc VascularAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer Research